Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state.

Ma Q, Sun H, Che E, Zheng X, Jiang T, Sun C, Wang S.

Int J Pharm. 2013 Jan 30;441(1-2):75-81. doi: 10.1016/j.ijpharm.2012.12.025. Epub 2012 Dec 21.

PMID:
23266761
2.

Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.

Yan YD, Sung JH, Kim KK, Kim DW, Kim JO, Lee BJ, Yong CS, Choi HG.

Int J Pharm. 2012 Jan 17;422(1-2):202-10. doi: 10.1016/j.ijpharm.2011.10.053. Epub 2011 Nov 6.

PMID:
22085435
3.

Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.

Li DX, Yan YD, Oh DH, Yang KY, Seo YG, Kim JO, Kim YI, Yong CS, Choi HG.

Drug Deliv. 2010 Jul;17(5):322-9. doi: 10.3109/10717541003717031.

PMID:
20367177
4.

Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths.

Zhang Y, Che E, Zhang M, Sun B, Gao J, Han J, Song Y.

Int J Pharm. 2014 Oct 1;473(1-2):375-83. doi: 10.1016/j.ijpharm.2014.07.024. Epub 2014 Jul 19.

PMID:
25051114
5.

Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.

Cao QR, Liu Y, Xu WJ, Lee BJ, Yang M, Cui JH.

Int J Pharm. 2012 Sep 15;434(1-2):325-33. doi: 10.1016/j.ijpharm.2012.05.076. Epub 2012 Jun 9.

PMID:
22688251
6.

Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.

Miao X, Sun C, Jiang T, Zheng L, Wang T, Wang S.

J Pharm Pharm Sci. 2011;14(2):196-214.

7.

Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.

Park YJ, Lee HK, Im YB, Lee W, Han HK.

Arch Pharm Res. 2010 Aug;33(8):1235-40. doi: 10.1007/s12272-010-0814-0. Epub 2010 Aug 28.

PMID:
20803127
8.

Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.

Nekkanti V, Pillai R, Venkateshwarlu V, Harisudhan T.

Pharm Dev Technol. 2009;14(3):290-8. doi: 10.1080/10837450802585278.

PMID:
19235553
9.

Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.

Marasini N, Tran TH, Poudel BK, Cho HJ, Choi YK, Chi SC, Choi HG, Yong CS, Kim JO.

Int J Pharm. 2013 Jan 30;441(1-2):424-32. doi: 10.1016/j.ijpharm.2012.11.012. Epub 2012 Nov 19.

PMID:
23174408
10.

Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process.

Kim MS, Baek IH.

Int J Nanomedicine. 2014 Nov 7;9:5167-76. doi: 10.2147/IJN.S71891. eCollection 2014.

11.

Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan.

Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR.

J Microencapsul. 2012;29(2):103-14. doi: 10.3109/02652048.2011.630106. Epub 2011 Nov 2.

PMID:
22047546
12.

Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan.

Lee JY, Kang WS, Piao J, Yoon IS, Kim DD, Cho HJ.

Drug Des Devel Ther. 2015 May 22;9:2745-56. doi: 10.2147/DDDT.S84070. eCollection 2015.

13.

Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate.

Zhang ZL, Le Y, Wang JX, Chen JF.

Drug Dev Ind Pharm. 2011 Nov;37(11):1357-64. doi: 10.3109/03639045.2011.575379. Epub 2011 May 6.

PMID:
21548718
14.

Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan.

Tran TT, Tran PH, Park JB, Lee BJ.

Arch Pharm Res. 2012 Jul;35(7):1223-30. doi: 10.1007/s12272-012-0713-7. Epub 2012 Aug 3.

PMID:
22864745
15.

Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.

Chella N, Tadikonda R.

Drug Dev Ind Pharm. 2015 Jun;41(6):888-97. doi: 10.3109/03639045.2014.911308. Epub 2014 May 5.

PMID:
24796274
16.

Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole.

Kumar S, Shen J, Burgess DJ.

J Control Release. 2014 Oct 28;192:95-102. doi: 10.1016/j.jconrel.2014.06.059. Epub 2014 Jul 7.

PMID:
25009979
17.

Comminution of ibuprofen to produce nano-particles for rapid dissolution.

Plakkot S, de Matas M, York P, Saunders M, Sulaiman B.

Int J Pharm. 2011 Aug 30;415(1-2):307-14. doi: 10.1016/j.ijpharm.2011.06.002. Epub 2011 Jun 12.

PMID:
21683776
18.

Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent.

Tran TH, Poudel BK, Marasini N, Chi SC, Choi HG, Yong CS, Kim JO.

Int J Pharm. 2013 Feb 25;443(1-2):50-7. doi: 10.1016/j.ijpharm.2013.01.013. Epub 2013 Jan 11.

PMID:
23318367
19.

A comparison between use of spray and freeze drying techniques for preparation of solid self-microemulsifying formulation of valsartan and in vitro and in vivo evaluation.

Singh SK, Vuddanda PR, Singh S, Srivastava AK.

Biomed Res Int. 2013;2013:909045. doi: 10.1155/2013/909045. Epub 2013 Jul 18.

20.

Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.

Li W, Yang Y, Tian Y, Xu X, Chen Y, Mu L, Zhang Y, Fang L.

Int J Pharm. 2011 Apr 15;408(1-2):157-62. doi: 10.1016/j.ijpharm.2011.01.059. Epub 2011 Feb 2.

PMID:
21295124
Items per page

Supplemental Content

Write to the Help Desk